UNAIDS, Global HIV. & AIDS statistics — Fact sheet 2024. [Available from: https://www.unaids.org/en/resources/fact-sheet. Accessed: December 15, 2024.

De Clercq J, Rutsaert S, De Scheerder M-A, Verhofstede C, Callens S, Vandekerckhove L. Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clin Belg. 2022;77(1):168–76.

Article  PubMed  Google Scholar 

Kreider EF, Bar KJ. HIV-1 reservoir persistence and decay: implications for cure strategies. Curr HIV/AIDS Rep. 2022;19(3):194–206.

Article  PubMed  PubMed Central  Google Scholar 

Li JZ, Aga E, Bosch RJ, Pilkinton M, Kroon E, MacLaren L, et al. Time to viral rebound after interruption of modern antiretroviral therapies. Clin Infect Dis. 2022;74(5):865–70.

Article  CAS  PubMed  Google Scholar 

Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9(2):e1003174.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rial-Crestelo D, Pinto-Martínez A, Pulido F. Cabotegravir and rilpivirine for the treatment of HIV. Expert Rev Anti Infect Ther. 2020;18(5):393–404.

Article  CAS  PubMed  Google Scholar 

Ndashimye E, Reyes PS, Arts EJ. New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates? FEMS Microbiol Rev. 2023;47(1).

Regueiro-Ren A, Sit SY, Chen Y, Chen J, Swidorski JJ, Liu Z, et al. The discovery of GSK3640254, a Next-Generation inhibitor of HIV-1 maturation. J Med Chem. 2022;65(18):11927–48.

Article  CAS  PubMed  Google Scholar 

Gulick RM, Flexner C. Long-Acting HIV drugs for treatment and prevention. Annu Rev Med. 2019;70:137–50.

Article  CAS  PubMed  Google Scholar 

World Health Organization (WHO). 2024. A seventh case of HIV cure reported at AIDS 2024.

Alum EU, Uti DE, Ugwu OP, Alum BN. Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A review. Med (Baltim). 2024;103(27):e38768.

Article  CAS  Google Scholar 

Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. Curr HIV/AIDS Rep. 2016;13(1):31–7.

Article  PubMed  PubMed Central  Google Scholar 

Vittecoq D, Mattlinger B, Barre-Sinoussi F, Courouce AM, Rouzioux C, Doinel C, et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis. 1992;165(2):364–8.

Article  CAS  PubMed  Google Scholar 

Jacobson JM, Colman N, Ostrow NA, Simson RW, Tomesch D, Marlin L, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993;168(2):298–305.

Article  CAS  PubMed  Google Scholar 

Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The passive hyperimmune therapy study group. Blood. 1994;84(7):2130–5.

Article  CAS  PubMed  Google Scholar 

Vittecoq D, Chevret S, Morand-Joubert L, Heshmati F, Audat F, Bary M, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci U S A. 1995;92(4):1195–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karpas A, Hewlett IK, Hill F, Gray J, Byron N, Gilgen D, et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A. 1990;87(19):7613–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jackson GG, Perkins JT, Rubenis M, Paul DA, Knigge M, Despotes JC, Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988;2(8612):647–52.

Article  CAS  PubMed  Google Scholar 

Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, Mariotti M, Lefrère F, Heshmati F, et al. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang. 1997;73(3):149–54.

CAS  PubMed  Google Scholar 

Armbruster C, Stiegler GM, Vcelar BA, Jäger W, Köller U, Jilch R, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother. 2004;54(5):915–20.

Article  CAS  PubMed  Google Scholar 

Morris GC, Wiggins RC, Woodhall SC, Bland JM, Taylor CR, Jespers V, et al. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS ONE. 2014;9(12):e116153.

Article  PubMed  PubMed Central  Google Scholar 

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11(6):615–22.

Article  CAS  PubMed  Google Scholar 

Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol. 2007;81(20):11016–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. J Infect Dis. 2021;223(3):370–80.

Article  CAS  PubMed  Google Scholar 

Thavarajah JJ, Hønge BL, Wejse CM. The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention. Viruses. 2024;16(6).

Kumar S, Singh S, Luthra K. An overview of human Anti-HIV-1 neutralizing antibodies against diverse epitopes of HIV-1. ACS Omega. 2023;8(8):7252–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harbor Perspect Med. 2012;2(1):a007039.

Article  Google Scholar 

Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayr LM, Su B, Moog C. Non-Neutralizing antibodies directed against HIV and their functions. Front Immunol. 2017;8:1590.

Article  PubMed  PubMed Central  Google Scholar 

Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, et al. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018;14(4):e1006987.

Article  PubMed  PubMed Central  Google Scholar 

Gruell H, Klein F. Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology. 2018;15(1):73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–22.

Article  CAS  PubMed  Google Scholar 

Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277–80.

Article  CAS  PubMed  PubMed Central